Short- and long-term outcomes of Roux-en-Y and Billroth II with Braun reconstruction in total laparoscopic distal gastrectomy: a retrospective analysis.
Humans
Retrospective Studies
Quality of Life
Bile Reflux
/ epidemiology
Stomach Neoplasms
/ surgery
Gastroenterostomy
/ adverse effects
Gastrectomy
/ adverse effects
Anastomosis, Roux-en-Y
/ adverse effects
Gastritis
Laparoscopy
/ adverse effects
Esophagitis, Peptic
/ epidemiology
Treatment Outcome
Postoperative Complications
/ epidemiology
Bile reflux
Billroth II with Braun
Long-term outcomes
Quality of life
Roux-en-Y
Total laparoscopic distal gastrectomy
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
22 Nov 2023
22 Nov 2023
Historique:
received:
04
08
2023
accepted:
13
11
2023
medline:
23
11
2023
pubmed:
22
11
2023
entrez:
22
11
2023
Statut:
epublish
Résumé
The controversy surrounding Roux-en-Y (R-Y) and Billroth II with Braun (BII + B) reconstruction as an anti-bile reflux procedure after distal gastrectomy has persisted. Recent studies have demonstrated their efficacy, but the long-term outcomes and postoperative quality of life (QoL) among patients have yet to be evaluated. Therefore, we compared the short-term and long-term outcomes of the two procedures as well as QoL. The clinical data of 151 patients who underwent total laparoscopic distal gastrectomy (TLDG) at the Gastrointestinal Surgery Department of the Second Hospital of Fujian Medical University from January 2016 to December 2019 were retrospectively analyzed. Of these, 57 cases with Roux-en-Y procedure (R-Y group) and 94 cases with Billroth II with Braun procedure were included (BII + B group). Operative and postoperative conditions, early and late complications, endoscopic outcomes at year 1 and year 3 after surgery, nutritional indicators, and quality of life scores at year 3 postoperatively were compared between the two groups. The R-Y group recorded a significantly longer operative time (194.65 ± 21.52 vs. 183.88 ± 18.02 min) and anastomotic time (36.96 ± 2.43 vs. 27.97 ± 3.74 min) compared to the BII + B group (p < 0.05). However, no other significant differences were observed in terms of perioperative variables, including blood loss (p > 0.05). Both groups showed comparable rates of early and late complications. Endoscopic findings indicated similar food residuals at years 1 and 3 post-surgery for both groups. The R-Y group had a lower occurrence of residual gastritis and bile reflux at year 1 and year 3 after surgery, with a statistically significant difference (p < 0.001). Reflux esophagitis was not significantly different between the R-Y and BII + B groups in year 1 after surgery (p = 0.820), but the R-Y group had a lower incidence than the BII + B group in year 3 after surgery (p = 0.023). Nutritional outcomes at 3 years after surgery did not differ significantly between the two groups (p > 0.05). Quality of life scores measured by the QLQ-C30 scale were not significantly different between the two groups. However, on the QLQ-STO22 scale, the reflux score was significantly lower in the R-Y group than in the BII + B group (0 [0, 0] vs. 5.56 [0, 11.11]) (p = 0.003). The rest of the scores were not significantly different (p > 0.05). Both R-Y and B II + B reconstructions are equally safe and efficient for TLDG. Nevertheless, the R-Y reconstruction reduces the incidence of residual gastritis, bile reflux, and reflux esophagitis, as well as postoperative reflux symptoms, and provides a better quality of life for patients. R-Y reconstruction is superior to BII + B reconstruction for TLDG.
Sections du résumé
BACKGROUND
BACKGROUND
The controversy surrounding Roux-en-Y (R-Y) and Billroth II with Braun (BII + B) reconstruction as an anti-bile reflux procedure after distal gastrectomy has persisted. Recent studies have demonstrated their efficacy, but the long-term outcomes and postoperative quality of life (QoL) among patients have yet to be evaluated. Therefore, we compared the short-term and long-term outcomes of the two procedures as well as QoL.
METHODS
METHODS
The clinical data of 151 patients who underwent total laparoscopic distal gastrectomy (TLDG) at the Gastrointestinal Surgery Department of the Second Hospital of Fujian Medical University from January 2016 to December 2019 were retrospectively analyzed. Of these, 57 cases with Roux-en-Y procedure (R-Y group) and 94 cases with Billroth II with Braun procedure were included (BII + B group). Operative and postoperative conditions, early and late complications, endoscopic outcomes at year 1 and year 3 after surgery, nutritional indicators, and quality of life scores at year 3 postoperatively were compared between the two groups.
RESULTS
RESULTS
The R-Y group recorded a significantly longer operative time (194.65 ± 21.52 vs. 183.88 ± 18.02 min) and anastomotic time (36.96 ± 2.43 vs. 27.97 ± 3.74 min) compared to the BII + B group (p < 0.05). However, no other significant differences were observed in terms of perioperative variables, including blood loss (p > 0.05). Both groups showed comparable rates of early and late complications. Endoscopic findings indicated similar food residuals at years 1 and 3 post-surgery for both groups. The R-Y group had a lower occurrence of residual gastritis and bile reflux at year 1 and year 3 after surgery, with a statistically significant difference (p < 0.001). Reflux esophagitis was not significantly different between the R-Y and BII + B groups in year 1 after surgery (p = 0.820), but the R-Y group had a lower incidence than the BII + B group in year 3 after surgery (p = 0.023). Nutritional outcomes at 3 years after surgery did not differ significantly between the two groups (p > 0.05). Quality of life scores measured by the QLQ-C30 scale were not significantly different between the two groups. However, on the QLQ-STO22 scale, the reflux score was significantly lower in the R-Y group than in the BII + B group (0 [0, 0] vs. 5.56 [0, 11.11]) (p = 0.003). The rest of the scores were not significantly different (p > 0.05).
CONCLUSION
CONCLUSIONS
Both R-Y and B II + B reconstructions are equally safe and efficient for TLDG. Nevertheless, the R-Y reconstruction reduces the incidence of residual gastritis, bile reflux, and reflux esophagitis, as well as postoperative reflux symptoms, and provides a better quality of life for patients. R-Y reconstruction is superior to BII + B reconstruction for TLDG.
Identifiants
pubmed: 37990273
doi: 10.1186/s12957-023-03249-6
pii: 10.1186/s12957-023-03249-6
pmc: PMC10664253
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
361Informations de copyright
© 2023. The Author(s).
Références
Gastroenterology. 1996 Jul;111(1):85-92
pubmed: 8698230
Ann Surg Oncol. 2022 Apr;29(4):2359-2367
pubmed: 34994886
Surg Endosc. 2018 Nov;32(11):4465-4471
pubmed: 29654529
J Gastrointest Surg. 2007 Dec;11(12):1732-40
pubmed: 17876675
Surg Endosc. 2022 Oct;36(10):7588-7596
pubmed: 35380283
Ann Surg. 2008 Jun;247(6):962-7
pubmed: 18520223
Surg Endosc. 2012 Jun;26(6):1539-47
pubmed: 22179454
Arch Pathol Lab Med. 2021 May 1;145(5):543-553
pubmed: 32223559
Am J Surg. 2005 Feb;189(2):178-83
pubmed: 15720986
Gastric Cancer. 2011 Oct;14(4):365-71
pubmed: 21573920
Yonsei Med J. 2014 Jan;55(1):162-9
pubmed: 24339302
Dig Dis Sci. 1993 Jun;38(6):1073-8
pubmed: 8508702
Cancer Manag Res. 2019 Feb 19;11:1697-1704
pubmed: 30863178
Ann Surg. 1980 Sep;192(3):288-98
pubmed: 7416826
Ann Med Surg (Lond). 2015 Sep 03;4(4):371-5
pubmed: 26904188
Am J Surg. 2018 Sep;216(3):528-533
pubmed: 29776645
Surg Laparosc Endosc Percutan Tech. 2014 Oct;24(5):448-51
pubmed: 24710243
Ann Surg. 2009 Feb;249(2):189-94
pubmed: 19212169
Gastroenterol Res Pract. 2017;2017:1803851
pubmed: 28163716
Front Oncol. 2020 Jul 31;10:1237
pubmed: 32850372
Int J Surg. 2015 Nov;23(Pt A):75-81
pubmed: 26384836
JAMA Surg. 2022 Jan 1;157(1):9-17
pubmed: 34668963
Am J Surg. 1988 Mar;155(3):490-4
pubmed: 3344916
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
J Gastrointest Surg. 2016 Jun;20(6):1083-90
pubmed: 27067234
J Gastric Cancer. 2014 Dec;14(4):229-37
pubmed: 25580354
Adv Ther. 2019 Nov;36(11):2997-3006
pubmed: 31605307
J Gastrointest Surg. 2014 May;18(5):906-10
pubmed: 24496746
Eur J Surg Oncol. 2019 Dec;45(12):2231-2240
pubmed: 31262598
Ann Surg. 1994 May;219(5):458-65; discussion 465-6
pubmed: 8185396
Gastric Cancer. 2002;5(2):83-9
pubmed: 12111583
Cancer Control. 2022 Jan-Dec;29:10732748221087059
pubmed: 35412845
Eur Urol. 2012 Aug;62(2):256-8; discussion 259-60
pubmed: 22521655
Ann Med Surg (Lond). 2022 Mar 28;76:103544
pubmed: 35495374
Ann Surg. 2015 Dec;262(6):910-24
pubmed: 25822684
Anesthesiology. 2021 Nov 1;135(5):904-919
pubmed: 34491303
Chin Med J (Engl). 2023 May 5;136(9):1074-1081
pubmed: 37014767
World J Surg. 2006 Jun;30(6):1043-9
pubmed: 16736335
Eur J Cancer. 2001 May;37(8):966-71
pubmed: 11334720
Wideochir Inne Tech Maloinwazyjne. 2021 Dec;16(4):664-668
pubmed: 34950260
Cancer Commun (Lond). 2021 Aug;41(8):747-795
pubmed: 34197702
Gastric Cancer. 2014;17(3):588-93
pubmed: 24178920
Surg Endosc. 2009 Oct;23(10):2374-9
pubmed: 19263143
World J Gastroenterol. 2016 Feb 28;22(8):2424-33
pubmed: 26937131
Surg Today. 2009;39(8):647-51
pubmed: 19639429